Services Get in touch

Home Aletta®

Discover how Aletta® sets a new standard for blood collection

Aletta®, the world’s first Autonomous Robotic Phlebotomy Device™ (ARPD™), automates the diagnostic blood collection process.

Patient punctured by Aletta

Addresses staffing shortages

Aletta® is designed to reduce workload, improve efficiency, and enhance the patient experience.

Performs a fully autonomous blood draw

Aletta® performs the entire blood draw on its own, from placing the tourniquet to applying the bandage.

Supports large-volume sites

In our model, one supervisor can oversee up to three Aletta® devices, making it ideal for busy blood draw centers.

Automating phlebotomy with Aletta® ARPD™

Aletta is designed to automate routine blood draws to reduce errors and ensure consistency.
Aletta aims to improve the patient experience by offering smoother blood draws and shorter wait times.
In our vision, one trained supervisor can oversee up to three Aletta devices, allowing phlebotomy departments to work manage staffing challenges.

Aletta is designed to perform the complete blood draw procedure autonomously. This includes identification of a suitable vein, inserting the needle, changing and inverting the tubes, and placing the bandage.

To locate a suitable vein, Aletta uses multimodal imaging that combines near infrared and ultrasound. In addition, the device uses Doppler ultrasound to confirm it has selected a vein and not an artery. Then, Aletta and positions and inserts the needle.

By automating these steps, Aletta aims to improve consistency and reduce variability in blood collection. This supports the shift towards fully automated laboratory workflows.

Today, Aletta has received CE mark certification in the European Union and is currently used in clinical trials.

Aletta is safe and accepted by patients

First-stick success rate with Aletta®

In the interim results of the A.D.O.P.T. trial, the first-time venipuncture success rate was 95%

Considers the pain less than or similar to manual

In the interim results of the A.D.O.P.T. trial, 85% of patients consider the pain less than or similar to a manual blood draw

Of patients accept a blood draw with Aletta®

In the interim results of the A.D.O.P.T. trial, 98% of patients indicate they accept a blood draw by the device

Mild adverse events with Aletta®

In the interim results of the A.D.O.P.T. trial, mild adverse events occurred in 1.3%. No moderate or serious adverse events occurred

Discover the value of Aletta® for you

For Hospital Leadership

A forward-looking approach to blood collection

Hospital and lab leadership can explore how Aletta fits into their long term innovation planning. As Aletta introduces a new supervised workflow for routine blood draws, phlebotomy departments shift to a standardized process.

Learn more

For Laboratory Specialists

Focus on preanalytical quality

Learn how Aletta supports blood collection through a supervised workflow. In addition, the A.D.O.P.T. trial interim results offer early insights into performance, safety, and patient acceptance.

Particularly, clinical chemists and lab managers can explore how autonomous phlebotomy is intended to strengthen preanalytical reliability, align with established laboratory processes, and bring more predictability to routine blood draws.

Learn more
Supervisor with Aletta

For Phlebotomists and Nurses

A new supervised workflow

Find out how Aletta® performs each step of a routine blood draw autonomously while staff remain in control through the supervisor role. Learn what the workflow looks like in practice.

Learn more

For Patients

A modern blood draw experience

Get an explanation of what it is like to have your blood drawn with Aletta. You will learn what you can expect during the process and how it works if you are invited to take part in the A.D.O.P.T. clinical study.

Learn more

Our clinical partners

Logo of OLVG Lab BV

OLVG Lab

OLVG Lab (Amsterdam, NL) is a clinical study site of the A.D.O.P.T. study and the first adopter of Aletta.

Logo of the St. Antonius hospital

St. Antonius

St. Antonius (Utrecht, NL) is a clinical study site of the A.D.O.P.T. study and an early adopter of Aletta.

Logo of Result laboratorium

Result Laboratorium

Result Lab (Dordrecht, NL) is a clinical study site of the A.D.O.P.T. study and an early adopter of Aletta.

Logo of Amsterdam UMC

Amsterdam UMC

Amsterdam UMC (Amsterdam, NL) is a clinical study site of the A.D.O.P.T. study and an early adopter of Aletta.

Customer Success

Implementation and training

We provide guidance through every stage of implementation. Supervisors are trained through the Vitestro Academy, and we offer on-site guidance to ensure a smooth go-live.
Read more

Patient education and engagement

We support our customers to educate and inform patients about Aletta®. By explaining the process, safety, and benefits, we help build trust and encourage participation.
Read more

Technical and professional services

We offer remote and on-site support, with proactive maintenance to ensure device uptime. We help optimize patient flow, queue management and integration.
Read more
Read more
Bob Gerberich

Bob Gerberich

Chief Commercial Officer

Let's get in touch

Do you have questions or want to learn more about Aletta®? Our team is ready to help you explore how Aletta can support your laboratory and improve patient care.